{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-238959","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2024-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.611261+00:00","generated_at":"2026-05-30T13:17:39.970345+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aura Biosciences: 4 of 5 low-grade NMIBC patients achieve clinical complete response with single-dose bel-sar","bullets":["Phase 1 trial of bel-sar in NMIBC: 4 of 5 low-grade patients had complete response (no tumor cells on histopathology).","2 of 3 high-grade patients showed visual tumor shrinkage on cystoscopy; immune activation observed in all evaluable patients.","Safety: only Grade 1 drug-related AEs in <10% of patients; no serious adverse events reported as of Sept 9, 2024 cutoff.","Evidence of bladder urothelial field effect in non-target tumors, suggesting broader immune response.","Company plans to expand Phase 1 and prepare for Phase 2 trial to evaluate durability of response."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-238959","json":"https://secwatch.observer/filing/0001193125-24-238959.json","markdown":"https://secwatch.observer/filing/0001193125-24-238959.md","text":"https://secwatch.observer/filing/0001193125-24-238959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312524238959/0001193125-24-238959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312524238959/d818130d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T13:17:39.970345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}